Specialty code 183500000X · Roseville, CA
NPI
1104488071
Since 2019
Specialty
Specialty code 183500000X
Code 183500000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
1011 Riverside Ave
Roseville, CA, 95678
Phone (916) 746-6827
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$422K
2,833 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Mariatou Sisay prescribed most often to Medicare patients was Atorvastatin Calcium, with 372 prescriptions and refills. In total Mariatou Sisay wrote 2,833 Medicare prescriptions that cost $422K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-12-02.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Atorvastatin Calcium Generic | 372 | 1,240 | 145 | $4,556 |
| Metformin Hcl Er Metformin Hcl | 323 | 1,071 | 119 | $3,305 |
| Glipizide Generic | 259 | 856 | 97 | $3,950 |
| Ozempic Semaglutide | 188 | 195 | 33 | $141K |
| Jardiance Empagliflozin | 163 | 535 | 63 | $106K |
| Humulin N Insulin Nph Human Isophane | 153 | 467 | 58 | $28K |
| Metformin Hcl Generic | 148 | 492 | 54 | $1,997 |
| Veo Insulin Syringe Syringe-Needle,insulin,0.5 Ml | 95 | 242 | 39 | $1,820 |
| Lisinopril Generic | 89 | 297 | 33 | $1,149 |
| Simvastatin Generic | 84 | 280 | 28 | $980 |
| Losartan Potassium Generic | 79 | 263 | 30 | $1,061 |
| Amlodipine Besylate Generic | 78 | 260 | 28 | $1,094 |
| Humulin R Insulin Regular, Human | 66 | 200 | 25 | $15K |
| Glipizide Er Glipizide | 64 | 213 | 25 | $1,956 |
| Insulin Glargine-Yfgn Generic | 59 | 161 | 31 | $10K |
Brand drugs: 809 claims; generic drugs: 1,807 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Mariatou Sisay were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.